Estradiol Patch 0.025mg

Route: Transdermal patch.

• Apply patch to clean, dry, intact hairless skin on the lower abdomen, buttocks, or hip — avoid the breasts, waistline (friction area), and irritated/broken skin.
• Apply once or twice weekly per the prescriber's directions (patch change frequency depends on the formulation matrix — most twice-weekly patches are changed every 3.5 days; once-weekly patches are changed every 7 days).
• Press firmly with the palm of the hand for 10 seconds to ensure full adhesion.
• Rotate application sites with each new patch to prevent skin irritation; do not apply to the same area for at least one week.
• Remove old patch before applying the new one; fold used patch in half (adhesive side together) and discard securely out of reach of children.
• If a patch falls off, replace it immediately and continue with the original patch-change schedule.

Dosing is prescriber-determined. 0.025 mg/day is considered a low starting dose for systemic menopausal hormone therapy. Key dosing considerations:

• Starting dose for estrogen-naive patients or those with mild symptoms.
• May be titrated upward to 0.0375, 0.05, 0.075, or 0.1 mg/day based on symptom response and serum estradiol monitoring.
• Women with an intact uterus require concurrent progestogen therapy.
• Reassess response and continued need at 3–6 month intervals.

• Estradiol (transdermal, 0.025 mg/day): The patch matrix releases 17β-estradiol at a controlled rate through the skin and stratum corneum into dermal capillaries, achieving systemic circulation without first-pass hepatic metabolism. Estradiol binds ERα and ERβ in target tissues, mediating genomic (ERE-driven transcription) and non-genomic (MAPK, PI3K via mERs) effects. At 0.025 mg/day, serum estradiol approximates low normal reproductive-age levels, providing moderate thermoregulatory and bone-protective effects while minimizing endometrial and breast stimulation.

Clinical Context: The 0.025 mg/day estradiol patch is used for initiation of systemic menopausal hormone therapy in patients with mild-to-moderate vasomotor symptoms, for bone density preservation in early postmenopause, or in patients with estrogen sensitivity requiring the lowest effective dose. Serum estradiol levels at this dose are typically 20–40 pg/mL, providing physiologic replacement without supraphysiologic exposure. May be combined with a progestogen patch or separate progestogen formulation in non-hysterectomized patients.

Monitoring:

• Serum estradiol at 4–8 weeks; adjust patch strength if symptoms persist or if estradiol is too high.
• Endometrial protection via progestogen in women with intact uterus.
• Annual mammography.
• Skin assessment at application sites for adhesion and local reactions.

Contraindications:

• Estrogen-dependent malignancies (breast, endometrial).
• Undiagnosed abnormal uterine bleeding.
• Active or prior VTE, PE, or arterial thromboembolism.
• Active hepatic disease or impairment.
• Known thrombophilic disorders.
• Pregnancy.

Warnings & Precautions:

• Endometrial cancer risk with unopposed estrogen: concurrent progestogen required in non-hysterectomized patients.
• Breast cancer risk with prolonged estrogen therapy — annual mammography essential.
• Patch adhesion: check daily; reapply if lifting at edges.
• Patch disposal: fold adhesive-side inward and discard out of reach of children and pets — residual estradiol in used patches can cause hormone exposure.

Drug Interactions:

• CYP3A4 inducers (rifampin, phenytoin, carbamazepine): reduce transdermal estradiol bioavailability.
• Thyroid replacement: estrogen increases TBG; monitor free thyroid hormone.

Common Side Effects: Application site reactions (erythema, pruritus, edema at patch site), breast tenderness, headache, and breakthrough spotting if progestogen coverage is insufficient.

Store at room temperature (below 30°C / 86°F); do not freeze. Store patches in original sealed pouches until use. Keep out of reach of children. Do not store in bathrooms (humidity may affect adhesion). Use before the beyond-use date assigned by Genesis Compounding. Dispose of used patches by folding adhesive-side together and placing in household trash (not flushing).

Why is 0.025mg considered a low-dose patch?

Commercially available estradiol patches range from 0.025 to 0.1 mg/day. The 0.025 mg/day dose produces the lowest systemic estradiol exposure while still providing meaningful relief for mild symptoms and bone protection. It is the typical starting dose for estrogen-naive patients or those requiring particularly conservative therapy.

How often do I change the patch?

Patch change frequency depends on the formulation (once-weekly or twice-weekly). The prescriber will specify the schedule. Most twice-weekly patches are changed on the same two days each week (e.g., Monday and Thursday). Mark your calendar to maintain adherence.

What should I do if the patch falls off?

Reapply the same patch to a new skin site as soon as possible and continue with your regular schedule. If it is close to the scheduled change day, apply a new patch and continue on the same schedule. Contact the prescriber if patches consistently fail to adhere.

Do I need progesterone with this patch?

If you have an intact uterus, yes — unopposed estrogen increases endometrial cancer risk. The prescriber will prescribe a progestogen (often progesterone) to use concurrently. Women who have had a hysterectomy generally do not require progestogen.

Is this FDA-approved?

FDA-approved estradiol transdermal patch products exist at this strength. This compounded patch from Genesis Compounding is a patient-specific 503A preparation under prescriber direction and is not itself FDA-approved as a compounded product.